Remove Coronary Artery Disease Remove Heart attacks Remove Ischemia
article thumbnail

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

DAIC

Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.

article thumbnail

FFRCT Slashes PAD + CAD Mortality

CardiacWire

A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheral artery disease surgeries has a massive impact on coronary artery disease detection, treatments, and long-term outcomes.

article thumbnail

Preventive Percutaneous Coronary Intervention for High-Risk Coronary Plaques Reduces Cardiac Events

DAIC

PCI is commonly used to open blocked arteries to treat significant myocardial ischemia , which occurs when the heart muscle does not get enough oxygenated blood. During PCI, an operator inserts a stent into a blocked artery through a catheter in the groin or arm. Patients were 64 years old, on average.

Plaque 111
article thumbnail

Do You Need A Stent To Treat Your Heart Disease?

Dr. Paddy Barrett

The second reason is commonly referred to as a ‘Heart Attack’ or acute coronary syndrome. This is an emergency and is most often treated with a stent to restore blood flow in the artery. The decision to use a stent here is usually clear and is associated with fewer deaths and heart attacks 1.

Stent 52
article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).